Compare Medpace Holdings Inc (MEDP) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Norwegian Cruise Line Holdings Ltd trades at $15.58 (market cap $7.11B). The key difference: Medpace Holdings Inc is far larger — about 2.4× Norwegian Cruise Line Holdings Ltd's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Norwegian Cruise Line Holdings Ltd for 68 Days on average.
| MEDP | NCLH | |
|---|---|---|
Market Cap | $16.82B | $7.11B |
Volume | 223,093 | 22,683,268 |
Sector | Health | Consumer Cyclical |
52-Week High | $630.19 | $25.02 |
52-Week Low | $393.42 | $14.12 |
Typical Hold Time | 14 Days | 68 Days |
Enterprise Value | $16.44B | $21.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
NCLH trades at $15.57, up 3.46% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.48, beating expectations, and expects Q3 results to exceed guidance. Valuation metrics appear attractive with a P/E of 9.39 and P/S of 0.75. Revenue has grown from $4.8B in 2022 to $9.83B in 2025, though net income margin declined to 4.3% from 9.6% in 2024.
The outlook is mixed: analyst consensus is bullish with a $20.86 price target, but the company faces yield pressure and high debt levels. Investment opportunity lies in continued operational recovery and compelling valuation, while risks include Caribbean pricing pressure and significant leverage that could constrain financial flexibility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
